Uncovering GPCR heteromer-biased ligands

Dalrymple, 2008, G protein-coupled receptor dimers: functional consequences, disease states and drug targets, Pharmacol. Ther., 118, 359, 10.1016/j.pharmthera.2008.03.004 Milligan, 2009, G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function, Br. J. Pharmacol., 158, 5, 10.1111/j.1476-5381.2009.00169.x Casado, 2009, GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers?, Pharmacol. Ther., 124, 248, 10.1016/j.pharmthera.2009.07.005 Violin, 2007, Beta-arrestin-biased ligands at seven-transmembrane receptors, Trends Pharmacol. Sci., 28, 416, 10.1016/j.tips.2007.06.006 Dromey, 2008, G protein coupled receptors as drug targets: the role of beta-arrestins, Endocr. Metab. Immune Disord. Drug Targets, 8, 51, 10.2174/187153008783928352 Kenakin, 2007, Functional selectivity through protean and biased agonism: who steers the ship?, Mol. Pharmacol., 72, 1393, 10.1124/mol.107.040352 Pfleger, 2008, Changes to gonadotropin-releasing hormone (GnRH) receptor extracellular loops differentially affect GnRH analog binding and activation: evidence for distinct ligand-stabilized receptor conformations, Endocrinology, 149, 3118, 10.1210/en.2008-0002 Holloway, 2002, Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors, Mol. Pharmacol., 61, 768, 10.1124/mol.61.4.768 Wisler, 2007, A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling, Proc. Natl. Acad. Sci. U.S.A., 104, 16657, 10.1073/pnas.0707936104 Maillet, 2007, A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties, FASEB J., 21, 2124, 10.1096/fj.06-7683com Milligan, 2007, Allosteric modulation of heterodimeric G-protein-coupled receptors, Trends Pharmacol. Sci., 28, 615, 10.1016/j.tips.2007.11.001 Kenakin, 2009, 7TM receptor allostery: putting numbers to shapeshifting proteins, Trends Pharmacol. Sci., 30, 460, 10.1016/j.tips.2009.06.007 Sexton, 2009, Modulating receptor function through RAMPs: can they represent drug targets in themselves?, Drug Discov. Today, 14, 413, 10.1016/j.drudis.2008.12.009 Hudson, 2010, Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor, Mol. Pharmacol., 77, 1, 10.1124/mol.109.060251 Glass, 1997, Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor, J. Neurosci., 17, 5327, 10.1523/JNEUROSCI.17-14-05327.1997 Jarrahian, 2004, D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor, J. Pharmacol. Exp. Ther., 308, 880, 10.1124/jpet.103.057620 Sohy, 2007, Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers, J. Biol. Chem., 282, 30062, 10.1074/jbc.M705302200 van Rijn, 2010, Opioid-receptor-heteromer-specific trafficking and pharmacology, Curr. Opin. Pharmacol., 10, 73, 10.1016/j.coph.2009.09.007 Waldhoer, 2005, A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers, Proc. Natl. Acad. Sci. U.S.A., 102, 9050, 10.1073/pnas.0501112102 Sharma, 2001, Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5′- to 6′-position of naltrindole, J. Med. Chem., 44, 2073, 10.1021/jm010095v van Rijn, 2009, The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake, Biol. Psychiatry, 66, 777, 10.1016/j.biopsych.2009.05.019 Mendez, 2004, [3H]DPDPE binding to delta opioid receptors in the rat mesocorticolimbic and nigrostriatal pathways is transiently increased by acute ethanol administration, Brain Res., 1028, 180, 10.1016/j.brainres.2004.09.010 Daniels, 2005, Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series, Proc. Natl. Acad. Sci. U.S.A., 102, 19208, 10.1073/pnas.0506627102 Rashid, 2007, D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum, Proc. Natl. Acad. Sci. U.S.A., 104, 654, 10.1073/pnas.0604049104 Milligan, 2006, G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery, Drug Discov. Today, 11, 541, 10.1016/j.drudis.2006.04.007 Milligan, 2007, Novel pharmacological applications of G-protein-coupled receptor–G protein fusions, Curr. Opin. Pharmacol., 7, 521, 10.1016/j.coph.2007.06.007 Carrillo, 2003, Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins, J. Biol. Chem., 278, 42578, 10.1074/jbc.M306165200 Pascal, 2005, Functional complementation and the analysis of opioid receptor homodimerization, Mol. Pharmacol., 68, 905, 10.1124/mol.105.013847 Han, 2009, Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation, Nat. Chem. Biol., 5, 688, 10.1038/nchembio.199 O’Dowd, 2006, A novel drug screening assay for G protein-coupled receptors, 51 O’Dowd, 2005, Dopamine receptor oligomerization visualized in living cells, J. Biol. Chem., 280, 37225, 10.1074/jbc.M504562200 O’Dowd, 2007, Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors, J. Biomol. Screen., 12, 175, 10.1177/1087057106298287 Pfleger, 2009, New technology to identify potential novel G-protein-coupled receptor heterodimers and heterodimer-specific compounds, J. Biomol. Screen, 14, 890 Ayoub, 2010, Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization, Curr. Opin. Pharmacol., 10, 44, 10.1016/j.coph.2009.09.012 Congreve, 2010, The impact of GPCR structures on pharmacology and structure-based drug design, Br. J. Pharmacol., 159, 986, 10.1111/j.1476-5381.2009.00476.x Ferre, 2009, Building a new conceptual framework for receptor heteromers, Nat. Chem. Biol., 5, 131, 10.1038/nchembio0309-131 Albizu, L. et al., (2010). Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. In Press Kenakin, 1995, Agonist-receptor efficacy. II. Agonist trafficking of receptor signals, Trends Pharmacol. Sci., 16, 232, 10.1016/S0165-6147(00)89032-X Millar, 2004, Gonadotropin-releasing hormone receptors, Endocr. Rev., 25, 235, 10.1210/er.2003-0002 Eglen, 2002, Enzyme fragment complementation: a flexible high throughput screening assay technology, Assay Drug Dev. Technol., 1, 97, 10.1089/154065802761001356 Doucette, 2009, Kappa opioid receptor screen with the Tango beta-arrestin recruitment technology and characterization of hits with second-messenger assays, J. Biomol. Screen., 14, 381, 10.1177/1087057109333974